Literature DB >> 23677414

A novel V(IV)O-pyrimidinone complex: synthesis, solution speciation and human serum protein binding.

Gisela Gonçalves1, Isabel Tomaz, Isabel Correia, Luís F Veiros, M Margarida C A Castro, Fernando Avecilla, Lorena Palacio, Miguel Maestro, Tamás Kiss, Tamás Jakusch, M Helena V Garcia, João Costa Pessoa.   

Abstract

The pyrimidinones mhcpe, 2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidinone ethyl ester (mhcpe, 1), 2,3-dimethyl-5-benzyloxy-6-carboxy-4-pyrimidinone ethyl ester (dbcpe, 2) and N-methyl-2,3-dimethyl-5-hydroxy-6-carboxyamido-4-pyrimidinone (N-MeHOPY, 3), are synthesized and their structures determined by single crystal X-ray diffraction. The acid-base properties of 1 are studied by potentiometric and spectrophotometric methods, the pK(a) values being 1.14 and 6.35. DFT calculations were carried out to determine the most stable structure for each of the H2L(+), HL and L(-) forms (HL = mhcpe) and assign the groups involved in the protonation-deprotonation processes. The mhcpe(-) ligand forms stable complexes with V(IV)O(2+) in the pH range 2 to 10, and potentiometry, EPR and UV-Vis techniques are used to identify and characterize the V(IV)O-mhcpe species formed. The results are consistent with the formation of V(IV)O, (V(IV)O)L, (V(IV)O)L2, (V(IV)O)2L2H(-2), (V(IV)O)L2H(-1), (V(IV)O)2L2H(-3), (V(IV)O)LH(-2) species and V(IV)O-hydrolysis products. Calculations indicate that the global binding ability of mhcpe towards V(IV)O(2+) is similar to that of maltol (Hmaltol = 3-hydroxy-2-methyl-4H-pyran-4-one) and lower than that of 1,2-dimethyl-3-hydroxy-4-pyridinone (Hdhp). The interaction of V(IV)O-complexes with human plasma proteins (transferrin and albumin) is studied by circular dichroism (CD), EPR and (51)V NMR spectroscopy. V(IV)O-mhcpe-protein ternary complexes are formed in both cases. The binding of V(IV)O(2+) to transferrin (hTF) in the presence of mhcpe involves mainly (V(IV)O)1(hTF)(mhcpe)1, (V(IV)O)2(hTF)(mhcpe)1 and (V(IV)O)2(hTF)(mhcpe)2 species, bound at the Fe(III) binding sites, and the corresponding conditional formation constants are determined. Under the conditions expected to prevail in human blood serum, CD data indicate that the V(IV)O-mhcpe complexes mainly bind to hTF; the formation of V(IV)O-hTF-mhcpe complexes occurs in the presence of Fe(III) as well, distinct EPR signals being clearly obtained for Fe(III)-hTF and to V(IV)O-hTF-mhcpe species. Thus this study indicates that transferrin plays the major role in the transport of V(IV)O-mhcpe complexes under blood plasma conditions in the form of ternary V(IV)-ligand-protein complexes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677414     DOI: 10.1039/c3dt50553g

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  4 in total

1.  Multiple and Variable Binding of Pharmacologically Active Bis(maltolato)oxidovanadium(IV) to Lysozyme.

Authors:  Giarita Ferraro; Maddalena Paolillo; Giuseppe Sciortino; Eugenio Garribba; Antonello Merlino
Journal:  Inorg Chem       Date:  2022-10-07       Impact factor: 5.436

2.  Biological sulfur in the blood cells of Ascidia ceratodes: XAS spectroscopy and a cellular-enzymatic hypothesis for vanadium reduction in the ascidians.

Authors:  Patrick Frank; Robert M K Carlson; Elaine J Carlson; Britt Hedman; Keith O Hodgson
Journal:  J Inorg Biochem       Date:  2020-01-07       Impact factor: 4.155

3.  ESI-MS Study of the Interaction of Potential Oxidovanadium(IV) Drugs and Amavadin with Model Proteins.

Authors:  Valeria Ugone; Daniele Sanna; Giuseppe Sciortino; Debbie C Crans; Eugenio Garribba
Journal:  Inorg Chem       Date:  2020-06-25       Impact factor: 5.165

Review 4.  Vanadium compounds in medicine.

Authors:  Joao Costa Pessoa; Susana Etcheverry; Dinorah Gambino
Journal:  Coord Chem Rev       Date:  2014-12-09       Impact factor: 22.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.